Brookstone Capital Management’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-15,185
| Closed | -$141K | – | 922 |
|
|
2023
Q4 | $141K | Hold |
15,185
| – | – | ﹤0.01% | 841 |
|
|
2023
Q3 | $84.9K | Buy |
15,185
+340
| +2% | +$1.9K | ﹤0.01% | 808 |
|
|
2023
Q2 | $121K | Hold |
14,845
| – | – | ﹤0.01% | 800 |
|
|
2023
Q1 | $121K | Hold |
14,845
| – | – | ﹤0.01% | 803 |
|
|
2022
Q4 | $148K | Buy |
14,845
+145
| +1% | +$1.45K | ﹤0.01% | 790 |
|
|
2022
Q3 | $155K | Sell |
14,700
-221
| -1% | -$2.33K | ﹤0.01% | 752 |
|
|
2022
Q2 | $191K | Buy |
14,921
+92
| +0.6% | +$1.18K | ﹤0.01% | 733 |
|
|
2022
Q1 | $168K | Buy |
14,829
+893
| +6% | +$10.1K | ﹤0.01% | 745 |
|
|
2021
Q4 | $216K | Hold |
13,936
| – | – | ﹤0.01% | 690 |
|
|
2021
Q3 | $246K | Hold |
13,936
| – | – | ﹤0.01% | 650 |
|
|
2021
Q2 | $354K | Buy |
+13,936
| New | +$354K | 0.01% | 549 |
|